UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease

Pharmacological reviews, 2013-01, Vol.65 (1), p.171-222

2013

Volltextzugriff (PDF)

Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque

PloS one, 2016-11, Vol.11 (11), p.e0167235-e0167235

2016

Volltextzugriff (PDF)

Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease

Journal of neuroinflammation, 2008-02, Vol.5 (1), p.8-8, Article 8

2008

Volltextzugriff (PDF)

Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism

Neurobiology of disease, 2017-10, Vol.106, p.133-146

2017

Volltextzugriff (PDF)

Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson's disease

Journal of neuroinflammation, 2023-03, Vol.20 (1), p.79-79, Article 79

2023

Volltextzugriff (PDF)

Brain-to-gut trafficking of alpha-synuclein by CD11c+ cells in a mouse model of Parkinson’s disease

Nature communications, 2023-11, Vol.14 (1), p.7529-7529, Article 7529

2023

Volltextzugriff (PDF)

Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson's disease mice

Journal of neuroinflammation, 2022-12, Vol.19 (1), p.319-319, Article 319

2022

Volltextzugriff (PDF)

Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein

Acta neuropathologica communications, 2020-02, Vol.8 (1), p.17-16, Article 17

2020

Volltextzugriff (PDF)

The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration

The Journal of neuroscience, 2010-12, Vol.30 (48), p.16091-16101

2010

Volltextzugriff (PDF)

The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease

Cells (Basel, Switzerland), 2020-03, Vol.9 (4), p.841

2020

Volltextzugriff (PDF)

Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein

PloS one, 2011-03, Vol.6 (3), p.e17698-e17698

2011

Volltextzugriff (PDF)

Animal models of α-synucleinopathy for Parkinson disease drug development

Nature reviews. Neuroscience, 2017-09, Vol.18 (9), p.515-529

2017

Volltextzugriff (PDF)

Enhanced firing of locus coeruleus neurons and SK channel dysfunction are conserved in distinct models of prodromal Parkinson’s disease

Scientific reports, 2022-02, Vol.12 (1), p.3180-3180, Article 3180

2022

Volltextzugriff (PDF)

Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease

Molecular neurodegeneration, 2010-10, Vol.5 (1), p.43-43

2010

Volltextzugriff (PDF)

l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease

Neuropharmacology, 2012-10, Vol.63 (5), p.829-836

2012

Volltextzugriff (PDF)

Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy

The Journal of neuroscience, 2009-03, Vol.29 (11), p.3365-3373

2009

Volltextzugriff (PDF)

Corrigendum to “Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism” [Neurobiol. Dis. 106 (2018) 133–146]

Neurobiology of disease, 2018-08, Vol.116, p.180-180

2018

Volltextzugriff (PDF)

Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression

Proceedings of the National Academy of Sciences - PNAS, 2009-12, Vol.106 (52), p.22474-22479

2009

Volltextzugriff (PDF)

The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease

Movement disorders, 2011-06, Vol.26 (7), p.1225-1233

2011

Volltextzugriff (PDF)

α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era

Trends in neurosciences (Regular ed.), 2016-11, Vol.39 (11), p.750-762

2016

Volltextzugriff (PDF)

Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α‐synuclein Parkinson's disease rat model

Annals of neurology, 2017-06, Vol.81 (6), p.825-836

2017

Volltextzugriff (PDF)

Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque

Neurobiology of aging, 2012, Vol.33 (1), p.207.e9-207.e19

2012

Volltextzugriff (PDF)

Bidirectional interaction between IL and 17A/IL-17RA pathway dysregulation and α-synuclein in the pathogenesis of Parkinson’s disease

Brain, behavior, and immunity, 2024-10

2024

Volltextzugriff (PDF)

Propagated α-synucleinopathy recapitulates REM sleep behaviour disorder followed by parkinsonian phenotypes in mice

Brain (London, England : 1878), 2020-12, Vol.143 (11), p.3374-3392

2020

Volltextzugriff (PDF)

GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease

Scientific reports, 2019-06, Vol.9 (1), p.8362, Article 8362

2019

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(63)

Publikationsform

Artikel
(70)
Dissertationen
(1)

Sprache

Englisch
(71)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease

Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque

Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease

Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism

Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson's disease

Brain-to-gut trafficking of alpha-synuclein by CD11c+ cells in a mouse model of Parkinson’s disease

Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson's disease mice

Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein

The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration

The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease

Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein

Animal models of α-synucleinopathy for Parkinson disease drug development

Enhanced firing of locus coeruleus neurons and SK channel dysfunction are conserved in distinct models of prodromal Parkinson’s disease

Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease

l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease

Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy

Corrigendum to “Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism” [Neurobiol. Dis. 106 (2018) 133–146]

Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression

The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease

α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era

Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α‐synuclein Parkinson's disease rat model

Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque

Bidirectional interaction between IL and 17A/IL-17RA pathway dysregulation and α-synuclein in the pathogenesis of Parkinson’s disease

Propagated α-synucleinopathy recapitulates REM sleep behaviour disorder followed by parkinsonian phenotypes in mice

GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease

Suchergebnisse filtern